ClinicalTrials.gg
RecruitingNCT06517810SAVEUpdated May 14, 2026

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

An observational study in Acute Kidney Injury and Acute Kidney Injury Due to Sepsis, sponsored by SeaStar Medical. Recruiting at 15 sites in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by SeaStar Medical · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
Up to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
92nd of 131
50 · median 124
Started
2024
with 23 others
Observational
132 of 370
21 open now
Primary completion
2026-05
later than 13 of 87 live
Registered
316th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 92nd largest by planned enrollment of the 131 observational ones that give a count, is one of 24 that started in 2024, is one of 132 observational ones, reaches primary completion later than 13 of the 87 other live ones, and was the 316th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: Up to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT.

The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator group of matched CKRT patients with sepsis who did not receive treatment with QUELIMMUNE

03

Conditions studied

  • Acute Kidney Injury
  • Acute Kidney Injury Due to Sepsis

Keywords

  • continuous kidney replacement therapy
  • continuous renal replacement therapy
  • acute kidney injury
  • organ failure
  • inflammation
  • dialysis
04

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients (weight ≥10kg and age ≤22 years) with acute kidney injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring renal replacement therapy (RRT), per device Instructions For Use. All patients who receive treatment with QUELIMMUNE as part of their therapy are included in this registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients initiated on QUELIMMUNE therapy under the HDE-approved indication

Exclusion criteria

Exclusion Criteria:

  • Weight \<10kg
  • Age >22 years
  • Known allergy to any components of QUELIMMUNE
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • QUELIMMUNE Surveillance Registry Participants

    All patients treated with the QUELIMMUNE device as a part of clinical practice under the approved HDE indication must be included in this registry.

    Device: QUELIMMUNE (SCD-PED)

Interventions

  • DeviceQUELIMMUNE (SCD-PED)

    QUELIMMUNE device used as part of clinical practice.

06

What researchers measure

Primary outcomes

  1. Safety

    New (secondary) bloodstream infections within 28 days from the time of QUELIMMUNE initiation or through hospital discharge, whichever is sooner

    Time frame: 28 days or through hospital discharge, whichever is sooner

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for May 2026, 22 months after the start.

Of 365 observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 24, 2024
StartActual
Jul 19, 2024
Primary completionEst.
May 2026
CompletionEst.
Aug 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06517810
Lead sponsor
SeaStar Medical
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Jul 19, 2024
Primary completion
May 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 14, 2026

Study contacts

Mohamed Zidan, MD
Contact
mzidan@seastarmed.com
844-427-8100
Kevin K Chung, MD
Contact
kchung@seastarmed.com
844-427-8100

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion